Net Revenue: Q4 net revenue increased by 31% to $168.4 million; full-year net revenue rose by 33% to $582.0 million. GAAP Net Income: Q4 GAAP net income was $26.6 million; full-year GAAP net income reached $128.9 million. 2024 Revenue Guidance: Projected net product revenue between $700 million to $720 million.
WAKIX® Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively U.S. Food and Drug Administration Granted.